- Previous Close
0.0000 - Open
3.1000 - Bid 2.7500 x 41800
- Ask 3.2400 x 36100
- Day's Range
3.1000 - 3.1000 - 52 Week Range
1.4100 - 3.1000 - Volume
15,000 - Avg. Volume
325 - Market Cap (intraday)
200.604M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
www.oryzon.comRecent News: ORYZF
View MorePerformance Overview: ORYZF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORYZF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORYZF
View MoreValuation Measures
Market Cap
192.94M
Enterprise Value
196.59M
Trailing P/E
--
Forward P/E
16.39
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
213.58
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--